Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
$314.40
-$0.58(-0.25%)
At close: 4:00 PM EST
$314.40
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$205.87 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.59M
Market Cap
$41.70B
Enterprise Value$43.01B
Total Cash (Recent Filing)$2.91B
Total Debt (Recent Filing)$2.97B
Price to Earnings (P/E)139.3
Beta1.02
Next Earnings
Apr 30, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.82
Shares Outstanding132,623,140
10 Day Avg. Volume1,932,684
30 Day Avg. Volume1,587,187
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue11.58
Enterprise Value/Gross Profit14.15
Enterprise Value/Ebitda90.99
Forecast
1Y Price Target
$457.33Price Target Upside45.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)7.14
Revenue Forecast (FY)$5.58B
Bulls Say, Bears Say
Bulls Say
Amvuttra Commercial MomentumStrong Amvuttra commercial sales are driving revenue expansion and have supported both GAAP and non‑GAAP profitability, indicating the product's contribution to financial stability.
Collaboration And Royalty Revenue VisibilityRevenue from collaborations and royalties, supported by partnerships with Roche and Regeneron and third‑party royalties, provides a diversified non‑product income stream that can smooth overall revenue.
Pipeline De‑risking Via Clinical ReadoutsUpcoming clinical data readouts from early‑stage programs in indications like hereditary hemorrhagic telangiectasia and Huntington's disease could materially de‑risk the pipeline and boost long‑term growth prospects.
Bears Say
Higher R&D And Operating Expense GuidancePlanned increases in R&D and operating spending have raised concerns about near‑term profitability and prompted investor requests for clearer detail on the spending plans.
Pricing, Reimbursement And Market Access PressuresPrice realignment in key markets, insurance reauthorizations, and expected net price declines in some regions could weigh on international and U.S. sales growth and create near‑term headwinds.
Revenue Recognition And Shipping TimingReduced scheduled shipping weeks and shipping calendar effects can lower recognized revenues and make reported sales appear weaker despite stable underlying demand.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $205.87 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $41.70B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 73 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 12, 2026. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.156 by -$0.336.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.07.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 132,623,140 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $0.82 in its last earnings report, missing expectations of $1.156. Following the earnings report the stock price went down -4.282%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$457.33 (45.46% Upside)
$457.33 (45.46% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 96%
Bearish news 4%
Bearish news 4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.69%
12-Months-Change
Fundamentals
Return on Equity
73.28%
Trailing 12-Months
Asset Growth
16.82%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive outlook supported by transformational 2025 results — nearly $3B product sales (81% YoY), robust Q4 performance, GAAP profitability, a deep and advancing pipeline (three Phase 3 starts) and ambitious 2030 goals — while responsibly acknowledging near-term headwinds including margin pressure from royalties, expected mid-single-digit net price declines, Q1 phasing impacts (notably a ~ $25M international adjustment), and higher planned R&D/SG&A investments. Management provided clear 2026 guidance (product revenue $4.9B–$5.3B, TTR $4.4B–$4.7B) and articulated how platform, pipeline, and manufacturing scale underpin sustained growth. Overall, the positives (strong growth, profitability, pipeline depth, funded strategy) materially outweigh the manageable near-term challenges.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$457.33
▲(45.46% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---